CFG
AKBA icon

Carr Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Carr Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7K Buy
15,581
+4,000
+35% +$5.5K 0.01% 174
2025
Q4 		$18.6K Buy
+11,581
New +$24.2K 0.01% 186

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Carr Financial Group's AKBA Position: Q1 2026 in Review

Carr Financial Group increased its Akebia Therapeutics (AKBA) stake by 35% in Q1 2026, buying an estimated $5.5K and bringing the position to 15,581 shares worth $21.7K. The position accounts for 0.01% of the portfolio, ranked #174.

Carr Financial Group first reported a position in AKBA in Q4 2025 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Carr Financial Group held 15,581 shares of Akebia Therapeutics worth $21.7K as of Q1 2026.
  • Carr Financial Group bought 4,000 Akebia Therapeutics shares in Q1 2026, an estimated $5.5K.
  • Akebia Therapeutics made up 0.01% of Carr Financial Group's portfolio in Q1 2026, its #174 holding.
  • Carr Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Carr Financial Group's 13F filing for Q1 2026, filed 12 May 2026.